AMG 510 First to Inhibit "Undruggable" KRAS.

Article Details

Citation
Copy to clipboard

Authors unspecified

AMG 510 First to Inhibit "Undruggable" KRAS.

Cancer Discov. 2019 Aug;9(8):988-989. doi: 10.1158/2159-8290.CD-NB2019-073. Epub 2019 Jun 12.

PubMed ID
31189530 [ View in PubMed
]
Abstract

Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRAS (G12C)-mutant non-small cell lung cancer, and led to stable disease in most evaluable patients with colorectal or appendix cancer.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
SotorasibGTPase KRasProteinHumans
Yes
Inhibitor
Details